Skip to main navigation Skip to search Skip to main content

A randomised, double-blind, placebo-controlled, parallel group, efficacy and safety study of empagliflozin (10mg, 25 mg) administrered orally, once daily over 24 weeks in hypertensive black/African American

University at Buffalo

Project: Research

Project Details

StatusFinished
Effective start/end date06/1/15 → 05/31/19

Funding

  • Boehringer Ingelheim Pharmaceutical: $113,523.72